Clarivate Plc Q3 FY2026 earnings call

• Strategic Focus: Completed the sale of the LS&H segment ahead of schedule, positioning Clarivate as a focused, high-quality recurring business centered on A&G and IP.
• AI Innovation: Deployed over 80 in-market AI agents; platform handled 465 million AI API calls (2.5x YoY). Web of Science Research Intelligence secured 100+ institutional wins. IP1 (AI-native layer) has 40 development partners and a pipeline of 151 customers.
• Commercial Traction: France selected Clarivate to modernize its national academic library system. USPTO selected Clarivate for image search in the trademark register.
• Operational Efficiency: Executed strategic wind-downs of low-margin transactional products (approx. 1% of revenue) and the A&G books business. Achieved $40 million in organic profit growth through cost efficiencies.
• Financial Discipline: Reduced leverage significantly, with $293 million in debt reduction year-to-date. Improved adjusted EBITDA margins by expanding them over 300 basis points in Q3 versus prior year.

The company operates two primary continuing segments following the sale of the Life Science & Healthcare (LS&H) division. The Academia and Government (A&G) segment is a $1.2 billion franchise with 95% recurring organic revenue mix, driven by strong institutional adoption of Web of Science. The Intellectual Property (IP) segment generates $800 million in revenue with a 90% recurring organic revenue mix, showing early signs of stabilization and renewed growth in new business acquisition.

• Full-Year 2026 Revenue: Expected range of $1.965 billion to $1.985 billion, down from prior year due to the wind-down of the A&G books business.
• Full-Year 2026 Adjusted EBITDA: Expected positive growth, ranging from $865 million to $885 million, with profit growth concentrated in Q4.
• Full-Year 2026 Free Cash Flow: Updated range of $320 million to $340 million, reflecting all divestiture transaction costs (~$30 million) being incurred.
• Organic KPIs: Organic ACV expected to range from 1.75% to 2.25%. Recurring organic revenue growth expected to be 1% to 1.5% for the full year, with Q4 exceeding 2%.
• Margin Expansion: Adjusted EBITDA margin expected to expand over 250 basis points, maintaining margins above 45% in Q4.
• 2027 Outlook: Targeting higher organic ACV and recurring revenue growth alongside increasing free cash flow and lower net leverage; full guidance to be provided in February.

• Foreign Exchange Volatility: Weakening of the U.S. dollar against foreign currencies impacted top-line revenue and created profit headwinds from currency fluctuations on costs.
• Execution Risk on AI Monetization: While AI deployment is scaled, converting customer interest and pipelines (e.g., Web of Science, IP1) into significant recurring revenue at scale remains a critical step.
• Disposal Impact: The wind-down of the A&G books business and other low-margin products creates near-term revenue declines, though these are offset by margin improvements.
• Competitive Landscape: Continued need to validate that proprietary data and workflow integration provide sufficient trust and defensibility against general-purpose AI models.

Q: Analyst Brandon Cohen asked about the drivers of the 1.8% organic ACV growth, specifically unpacking the price versus volume dynamic and what is needed to make retention and new sales bigger drivers of acceleration into Q4 and 2027.

A: CFO Michael Easton confirmed that pricing, targeting around 3%, was a primary driver of the current ACV growth. He noted that volumes are also improving. The company aims to exit the year with 2% ATD growth, expecting further improvement as they move into 2027, indicating a strategy where pricing leads initially while volume and retention gains compound over time.

Q: Analyst Alex Flacker questioned how IP segment ACV returned to positive growth for the first time in three years while total segment organic revenue declined 0.4%, asking what drives this ACV improvement and how it translates to future organic revenue growth within the broader IP ecosystem.

A: CEO Mahdi Shem Tov explained that IP has stabilized through management changes, a more focused sales organization, and a return to 1% recurring revenue growth. He highlighted confidence in the new IP1 agentic AI platform, which is designed not only to drive new bookings but also to improve subscription retention, signaling that the ACV recovery is foundational to reversing the revenue decline trend.

Q: Analyst Abe Landa asked for details on how Clarivate plans to use proceeds from the LS&H divestiture to repay the 2028 and 2029 notes at a discount, including the specific process and how the company weighs buying back one note series versus the other given their different maturity dates.

A: CFO Michael Easton stated that the company has already repurchased approximately $290 million of debt year-to-date at a 2-3% discount. For Q4, they plan to continue this approach, seeking opportunities to complete buybacks in short order. Regarding the choice between 2028 and 2029 notes, he emphasized balancing the opportunity to reduce litigation (duration risk) against the timing of maturities and overall capital structure optimization using available cash proceeds.